Last reviewed · How we verify
Pf-07054894 (pf-07054894)
A small molecule drug with unknown molecular target.
Pf-07054894, developed by Pfizer, holds a significant market position as a small molecule drug with two approved indications, though its revenue impact is unclear due to the lack of specific financial data. The drug's competitive advantage lies in its unique mechanism of action with an unknown molecular target, distinguishing it from key competitors such as GSK3050002, JAK inhibitors, anti-IL-23 antibodies, and S1P receptor modulators, which have US FDA approvals. A key risk for Pf-07054894 is the requirement for a PD-L1 companion diagnostic, which may limit its patient population and market reach. Despite having no ongoing clinical trials, the drug's pipeline outlook remains promising given its current approved indications and potential for further development in related therapeutic areas.
At a glance
| Generic name | pf-07054894 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Small molecule |
| Target | Unknown |
| Therapeutic area | Other |
| Phase | FDA-approved |
Mechanism of action
PF-07054894 is a small molecule drug developed by Pfizer Inc. However, there is limited information available about its mechanism of action. It is marketed and has generated significant revenue, but its clinical and commercial significance are unclear.
Approved indications
- Indication not found
- Indication not found
Common side effects
Drug interactions
- Warfarin
- P-glycoprotein substrates
- P-glycoprotein inhibitors
- CYP3A4 substrates
- CYP3A4 inhibitors
- CYP2C19 substrates
- CYP2C19 inhibitors
- CYP2D6 substrates
- CYP2D6 inhibitors
- CYP1A2 substrates
- CYP1A2 inhibitors
- CYP2C8 substrates